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Abstract Electrospray ionisation mass spectrometry was
used to analyse the reactions of metal compounds with
mixtures of selected proteins. Three representative medic-
inally relevant compounds, cisplatin, transplatin and the
organometallic ruthenium compound RAPTA-C, were
reacted with a pool of three proteins, ubiquitin, cytochrome
c and superoxide dismutase, and the reaction products were
analysed using high-resolution mass spectrometry. Highly
informative electrospray ionisation mass spectra were
acquired following careful optimisation of the experimen-
tal conditions. The formation of metal–protein adducts was
clearly observed for the three proteins. In addition, valu-
able information was obtained on the nature of the protein-
bound metallofragments, on their distribution among the
three different proteins and on the binding kinetics. The
platinum compounds were less reactive and considerably
less selective in protein binding than RAPTA-C, which
showed a high affinity towards ubiquitin and cytochrome c,
but not superoxide dismutase. In addition, competition
studies between cisplatin and RAPTA-C showed that the
two metallodrugs have affinities for the same amino acid
residues on protein binding.
Keywords Cisplatin  Metal-based drugs  Proteins 
Bioorganometallic chemistry  Mechanism of action
Introduction
Platinum-based compounds are widely used in the treat-
ment of cancer [1]. However, in recent years a vast number
of non-platinum compounds has been prepared and eval-
uated as experimental anticancer drugs [2–6]. Among
them, ruthenium(II)-arene complexes bearing 1,3,5-triaza-
7-phosphaadamantane (pta) ligands—named ‘RAPTA’
[7]—have been found to exhibit promising antimetastatic
properties in vivo, and appear to function in a way different
from cisplatin. [8–10] Indeed, ruthenium complexes could
prove to be effective alternatives to those based on platinum,
and trans-[tetrachloro(dimethyl sulphoxide)(imidazole)
ruthenate(III)] (NAMI-A) [11] and trans-[tetrachlorobis
(1H-indazole)ruthenate(III)] (KP1019) [12] have both
completed phase I clinical trials.
Since DNA is considered as the primary target for
platinum metallodrugs [13, 14], interest in the field has
mainly focused on the characterisation of metal complex–
nucleic acid adducts, with considerably less attention being
paid to other potential biomolecular targets. However, the
mechanisms of action of ruthenium-based anticancer
compounds are comparatively unexplored, although it is
clear that ruthenium compounds interact far more weakly
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with DNA relative to platinum compounds [15]. There is
evidence to suggest that ruthenium compounds might
directly interfere with specific proteins involved in signal
transduction pathways and/or alter cell adhesion and
migration processes [10, 16, 17].
Within this frame, it is of particular interest to develop
specific methods to analyse the reactivity of metallodrugs
towards potential cellular targets, in particular proteins and
enzymes. Moreover, protein-bound metallofragments
potentially represent the actual active anticancer species
present in vivo—rather than simple drug activation prod-
ucts—provided that transfer of the metal among specific
binding sites is kinetically favoured [18]. In addition,
metallation of specific amino acid residues, affecting the
function of biologically crucial proteins through the for-
mation of strong coordination (covalent) bonds, might play
a relevant role in the overall toxicological profile of metal-
based drugs [19–21]. Indeed, a number of reviews on
metallodrug–protein interactions have been published that
explore various aspects of their relevance to anticancer
activity [22–24].
In recent years, electrospray ionisation (ESI) mass
spectrometry (MS) has emerged as an extremely valuable
and powerful method to monitor the formation of protein
adducts of classic and new-generation metallodrugs,
even allowing the binding site of the resulting metallic
fragment(s) to be ascertained [25, 26]. However, the opti-
misation and the standardisation of experimental ESI MS
procedures directed to metallodrugs require attention, since
the variability in the ESI MS response depends on many
factors, such as the nature of the protein, the nature of the
metal/ligands/charge and the specific solution conditions
(pH, buffer, etc.) [27, 28].
The reactivity of several metal anticancer compounds
with model proteins such as cytochrome c or ubiquitin has
been studied using ESI MS [29–32]. Combined, these
studies show that ESI MS allows rapid and unambiguous
identification of the nature of protein-bound metal-con-
taining molecular fragments. However, the studies
undertaken to date do not provide direct information on the
actual selectivity of the metal compound towards a certain
protein in the presence of other proteins, or provide any
information on compound selectivity with respect to pro-
tein binding. Accordingly, herein we describe a novel high-
resolution ESI MS approach to study the reactions of metal
complexes [cisplatin, transplatin and an arene-capped
ruthenium(II) compound Ru(g6-p-cymene)(pta)Cl2, RAP-
TA-C; Fig. 1] with a mixture of three different model
proteins (cytochrome c, ubiquitin and superoxide dismu-
tase, SOD). In addition, competitive binding of a mixture
of cisplatin and RAPTA-C with the protein mixture was
studied, providing insights into their preferred binding
sites. As far as we are aware, this is the first time that such
approaches involving protein mixtures have been used to
study metal-based drugs.
It is worth mentioning that while the proteins were
selected as a model system for evaluation/optimisation of
the approach, they each have important functions relevant
to cancer. Cytochrome c is an important protein crucially
involved in apoptotic pathways [33], ubiquitin is relevant
in posttranslational modification of proteins together with
the proteasome system [34] and SOD is relevant to human
diseases by catalysing the conversion of single-electron-
reduced species of molecular oxygen to hydrogen peroxide
and oxygen [35]. Of particular relevance to this study,
these proteins have characteristics that make them suitable
for MS analysis; they are of small to moderate size, with
molecular mass ranging from 6,500 to 15,000 Da (SOD in
the monomeric form). Moreover, they are commercially
available, manifest a high stability in solution under
physiological-type conditions and are water-soluble. In
most cases, they are easy ionisable and optimal for ESI MS
detection in positive ion mode. In addition, for all these
proteins high-resolution crystal structures or NMR struc-
tural data are available that complement the identification
of the probable metal binding sites (e.g. the most-surface-
exposed residues).
Materials and methods
Metal complexes and proteins
Horse heart cytochrome c, red blood cell ubiquitin and
bovine erythrocyte SOD were purchased from Sigma
(C7752, U6253 and S2515, respectively) and used as
received. Cisplatin and transplatin were obtained from
Sigma and RAPTA-C was prepared using a literature
method [4].
Sample preparation and mass-spectrometric analysis
Samples were prepared by mixing equivalent amounts of
the three proteins (100 lM) in 25 mM tetramethylammo-
nium acetate buffer (pH 7.4). Then each of the selected
metal complexes was added to the solutions (5:1 metal-to-
protein ratio) and incubated at 37 C for different time
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Fig. 1 Structures of the metal complexes employed in this study
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intervals. Prior to analysis, samples were extensively
ultrafiltered using a Centricon YM-3 filter (Amicon Bio-
separations, Millipore Corporation) to remove the unbound
complex. For the competition experiments, proteins sam-
ples containing both cisplatin and RAPTA-C (5:1 metal-
to-protein ratio) were prepared as described above and
analysed by MS over a period of 48 h. In a second type of
competition experiment, proteins samples containing either
cisplatin or RAPTA-C (5:1 metal-to-protein ratio) were
prepared as previously described and incubated for 72 h at
37 C. Then an excess (5:1 metal-to-protein ratio) of the
second metal complex (RAPTA-C or cisplatin) was added
and the incubation was continued for another 24 h. Each
sample was analysed in triplicate.
After a 20-fold dilution with HCOOH (0.1%), ESI MS
spectra were recorded by direct introduction at a 3 lL/min
flow rate into an LTQ-Orbitrap high-resolution mass
spectrometer (Thermo, San Jose, CA, USA), equipped
with a conventional ESI source. The working conditions
comprised the following: spray voltage 3.1 kV, capillary
voltage 45 V and capillary temperature 220 C. The sheath
and the auxiliary gases were set, respectively, at 17 (arbi-
trary units) and 1 (arbitrary unit). For acquisition, Xcalibur
2.0 software (Thermo) was used and monoisotopic and
average deconvoluted masses were obtained by using the
integrated Xtract tool. For spectra acquisition, a nominal
resolution (at m/z 400) of 100,000 was used.
Results and discussion
High-resolution LTQ-Orbitrap ESI MS [36] was used to
monitor the adducts formed between cisplatin, transplatin
and the organometallic compound RAPTA-C with a mix-
ture of three proteins in solution (cytochrome c, ubiquitin
and SOD). High-resolution ESI MS has previously been
used to study covalent and non-covalent ligand–biomole-
cule interactions [37, 38] and to screen complex mixtures
of metabolites [39–41], often without the need for chro-
matographic separation of the adducts prior to analysis.
Hence, this method allows the simultaneous screening
of complicated mixtures of compounds with the direct
Fig. 2 LTQ-Orbitrap electrospray ionisation (ESI) mass spectra of a
mixture of ubiquitin (Ub), cytochrome c (cyt c) and superoxide
dismutase (SOD) (1:1:1) in tetramethylammonium acetate (TMeA-
mAc) buffer pH 7.4 and the same protein mixture after 24-h
incubation at 37 C with cisplatin, transplatin and RAPTA-C,
respectively (5:1 metal-to-protein ratio). Peaks corresponding to the
main adducts have been assigned as follows: 1a Ub–Pt(NH3)2; 2a cyt
c–Pt(NH3)2; 3a SOD–Pt(NH3)2; 1b Ub–[Pt(NH3)Cl]; 2b cyt c–
Pt(NH3)2; 3b SOD–[Pt(NH3)Cl]; 1c Ub–[Ru(g
6-p-cymene)]; 2c
Ub ? 2[Ru(g6-p-cymene)]; 3c Ub–[Ru(g6-p-cymene)(pta)] ? Ub–
[Ru(g6-p-cymene)]; 4c cyt c–[Ru(g6-p-cymene)]; 5c cyt c–[Ru
(g6-p-cymene)(pta)]; 6c cyt c–[Ru(g6-p-cymene)(pta)] ? cyt c–[Ru
(g6-p-cymene)]; 7c SOD–[Ru(g6-p-cymene)(pta)Cl]. pta is 1,3,5-
triaza-7-phosphaadamantane
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identification of the reaction products, i.e. metallodrug–
protein adducts. Although ESI MS is not a quantitative
technique, it can be used to screen multicomponent
systems, providing a semiquantitative description of the
abundance of the species in solution [42]. Typically, ESI
MS has been applied to establish the affinity of multiple
potential ligands for a single macromolecular target;
however, related procedures have been used to study
ligand binding to (and affinity for) a protein mixture [38].
Moreover, Will et al. [43, 44] have recently demonstrated
the suitability of an automated method for shotgun pro-
teomics based on ESI MS for establishing some of the
protein targets of transition metal complexes in whole-cell
systems.
Deconvoluted mass spectra of the mixture of the three
proteins incubated with each of the selected compounds
(5:1 metal-to-protein ratio) in aqueous solution at pH 7.4,
for 24 h at 37 C, are shown in Fig. 2 together with a
spectrum of the untreated protein mixture for comparison
purposes. A list of the main peaks is given in Table 1.
The untreated protein sample (Fig. 2) shows three well-
separated peaks at 8,564.6, 12,358.3 and 15,590.8 Da
corresponding to the molecular masses of ubiquitin,
cytochrome c and SOD, respectively.
The deconvoluted mass spectrum of the proteins incu-
bated with cisplatin (Fig. 2) shows numerous additional
peaks. A series of peaks centred at 8,791.6 Da corresponds
to platinum monoadducts, the most intense one (15-20%
relative intensity) in which a single [Pt(NH3)2]
2? fragment is
coordinated to ubiquitin (see Table 1 for all peak assign-
ments). A similar pattern is found in the case of cytochrome
c and SOD adducts, in which peaks at 12,585.4 Da
(15–20% relative intensity) and at 15,817.8 Da (15–20%
relative intensity) correspond to the proteins with a single
[Pt(NH3)2]
2? fragment bound. A [Pt(NH3)]
2? fragment
attached to ubiquitin and cytochrome c is also observed (see
Table 1), albeit with low relative intensity (5–10% relative
intensity), in which an ammonia ligand has been lost. These
data match well with those from previous studies of cisplatin
binding to single proteins [22, 26, 27]. All of the monopla-
tinated protein species are of approximately equal relative
intensity (totalling around 10–20% relative intensity) with
respect to the free protein signals, demonstrating that cis-
platin reacts with each protein in the mixture to a similar
extent.
The reactivity of transplatin with the mixture of proteins
was also evaluated to establish the differences in reactivity
between cisplatin and its inactive isomer. Overall, the
behaviour of transplatin is very similar to that of cisplatin
(Fig. 2, Table 1), with the [Pt(NH3)2]
2? fragment being the
most common species formed. However, for transplatin,
loss of ammonia is not observed since it is not labilised by
a trans effect on protein binding. Instead, peaks corre-
sponding to species containing [Pt(NH3)2Cl]
? fragments
are observed. In contrast to cisplatin, a slight preference for
cytochrome c binding can be inferred from the relative
intensities of the adducts relative to the free proteins (25–
30% relative intensity for the cytochrome c adducts com-
pared to only 5–10% relative intensity for the adducts with
ubiquitin and SOD).
The spectrum of the proteins incubated with RAPTA-C
(Fig. 2) shows marked differences with respect to the
spectrum of protein mixture incubated with the platinum
compounds. Overall, a considerably higher reactivity of
RAPTA-C is observed, with the most abundant adduct
peaks being obtained with ubiquitin and cytochrome c
(approximately 70–80% relative intensity). In fact, after
24 h both monoruthenium and bisruthenium adducts are
formed with ubiquitin and cytochrome c (Table 1). In all
cases, peaks corresponding to [(g6-cymene)Ru]2? and [(g6-
cymene)(pta)Ru]2? fragments are detected, but with dif-
ferent relative intensities, the pta-containing adduct being
less intense. Notably, RAPTA-C shows a marked selec-
tivity for cytochrome c and ubiquitin binding, with adduct
peaks of greater relative intensity than the peaks of the
Table 1 Main peaks identified in the deconvoluted mass spectra of
cisplatin-, transplatin- and Ru(g6-p-cymene)(pta)Cl2 (RAPTA-C)-
treated protein mixtures after 24-h incubation at 37 C
Compound Mass (Da) Protein–metal adduct
Cisplatin 8,774.6 Ub–Pt(NH3)
8,791.6 Ub–Pt(NH3)2
12,569.3 Cyt c–Pt(NH3)
12,585.4 Cyt c–Pt(NH3)2
15,817.8 SOD–Pt(NH3)2
Transplatin 8,791.6 Ub–Pt(NH3)2
8,827.6 Ub–[Pt(NH3)2Cl]
12,585.3 Cyt c–Pt(NH3)2
12,622.3 Cyt c–[Pt(NH3)2Cl]
15,817.8 SOD–Pt(NH3)2
15,853.8 SOD–[Pt(NH3)2Cl]
RAPTA-C 8,797.6 Ub–[Ru(g6-p-cymene)]
9,031.6 Ub ? 2[Ru(g6-p-cymene)]
9,188.7 Ub–[Ru(g6-p-cymene)(pta)]
? Ub–[Ru(g6-p-cymene)]
9,223.7 Ub–[Ru(g6-p-cymene)(pta)Cl]
? Ub–[Ru(g6-p-cymene)]
12,592.3 Cyt c–[Ru(g6-p-cymene)]
12,749.4 Cyt c–[Ru(g6-p-cymene)(pta)]
12,983.4 Cyt c–[Ru(g6-p-cymene)(pta)]
? cyt c–[Ru(g6-p-cymene)]
15,822.8 SOD–[Ru(g6-p-cymene)]
16,017.9 SOD–[Ru(g6-p-cymene)(pta)Cl]
Ub ubiquitin, cyt c cytochrome c, SOD superoxide dismutase, pta
1,3,5-triaza-7-phosphaadamantane
764 J Biol Inorg Chem (2009) 14:761–770
123
unbound proteins, whereas for SOD only adducts of low
relative intensity are observed (10–15% relative intensity).
These findings demonstrate that the organometallic ruthe-
nium compound has a greater affinity towards protein
binding than cisplatin (and transplatin), but also that the
compound has an intrinsic selectivity towards certain pro-
teins (see below).
Kinetic studies were performed to further characterise
protein binding of RAPTA-C. Spectra of the mixture of the
three proteins treated with RAPTA-C were analysed at
different time intervals over a period of 24 h and the
spectra obtained are compiled in Fig. 3, with assignments
given in Table 2. After 3 h, peaks with low relative
intensities corresponding to ruthenium-bound fragments
are detected. Specifically, peaks at approximately 8,798
and 12,749 Da (5–10% relative intensity) correspond to
monoadducts of [Ru(g6-p-cymene)]2? and [Ru(g6-p-cym-
ene)pta]2? species with ubiquitin and cytochrome c,
respectively. It is noteworthy that the [Ru(g6-p-cymene)]2?
fragment in which the pta and chloride ligands have
been lost forms preferentially with ubiquitin, whereas with
cytochrome c the only coordinated fragment is [Ru(g6-p-
cymene)pta]2?, which retains the pta ligand. No adducts
with SOD are observed at this time. After 6 h, the spectrum
contains the same series of peaks, but the relative intensi-
ties of the adduct peaks have increased relative to the peaks
of the free proteins. In addition, the signal of a [Ru(g6-p-
cymene)]2? fragment bound to cytochrome c appears at
approximately 12,592 Da (10% relative intensity). After
12-h incubation, all the signals corresponding to ruthenium
adducts increase in intensity. Remarkably, a net increase of
the cytochrome c–[Ru(g6-p-cymene)]2? adduct (60% rel-
ative intensity) is observed. Notably, at 12 h no adducts
with SOD are observed. After 24-h incubation, the situation
is essentially the same (Fig. 2, Table 1), except minor
adducts with SOD are observed.
The competitive binding of cisplatin and RAPTA-C
towards the protein mixture was also studied. Samples were
prepared by mixing the three proteins with an excess of
cisplatin and RAPTA-C. Through this approach it was
possible to establish if the two complexes compete for the
same binding sites or if they target different amino acid
Fig. 3 Time-dependent mass-spectrometric analysis of the protein
mixture treated with RAPTA-C (5:1 metal-to-protein ratio) in
TMeAmAc buffer pH 7.4 and incubated for 3, 6 and 12 h at 37 C.
The mass peaks were assigned as follows: 1a, 1b 1c Ub–[Ru(g6-p-
cymene)]; 2a, 3b, 4c cyt c–[Ru(g6-p-cymene)(pta)]; 2b Ub–[Ru(g6-p-
cymene)(pta)Cl]; 2c Ub–[Ru(g6-p-cymene)(pta)] ? Ub–[Ru(g6-p-
cymene)]; 3c cyt c–[Ru(g6-p-cymene)]; 5c cyt c–[Ru(g6-p-cyme-
ne)(pta)] ? cyt c–[Ru(g6-p-cymene)]
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residues. The incubation mixture was analysed at different
times over a 48-h period. Selected areas of the ESI MS
spectra recorded at different times are reported in Fig. 4.
After 24 h, it was possible to identify the signals corre-
sponding to the ubiquitin–[Ru(g6-p-cymene)]2? adduct
at approximately 8,797 Da (approximately 30% relative
intensity), while no cisplatin–ubiquitin species were
detected (Fig. 4a). The same ruthenium adduct was the only
metal-containing species detected after 48 h, and increased
in relative intensity to become the predominant species with
respect to unbound ubiquitin (Fig. 4a). In the case of
cytochrome c and SOD, cytochrome c–Pt(NH3)2H2O and
SOD–Pt(NH3)2 adducts were detected at approximately
12,604 Da (approximately 10% relative intensity) (Fig. 4b)
and approximately 15,818 Da (approximately 10% relative
intensity) (data not shown), respectively. After 48 h, the
cytochrome c–[Ru(g6-p-cymene)]2? adduct appears at
approximately 12,591 Da (approximately 10% relative
intensity). Remarkably, no ruthenium adducts with SOD
were detected.
Overall, these spectra suggest that RAPTA-C competes
with cisplatin for the same binding sites on the three
selected proteins. In fact, it has been shown that when one
of the two complexes forms adducts, the other one is not
able to react or at least its binding is highly reduced. With
respect to ubiquitin, the most reactive metallodrug is
RAPTA-C. Remarkably, in the case of cytochrome c,
neither complex dominates and the corresponding relative
intensities remain in the range 10–20%.
In a further series of experiments, cisplatin was reacted
with the three proteins and then an excess of RAPTA-C
was added (see ‘‘Sample preparation and mass-spectro-
metric analysis’’ for full details). This alternative approach
was applied to confirm the affinity of the two complexes
for the same binding sites, but without disrupting the
physiological-like conditions, which is the case when an
excess of the two drugs is employed at the same time, as
reported above. The spectra obtained are shown in Fig. 5,
with Fig. 5a focusing on the region containing peaks for
ubiquitin and its adducts. In Fig. 5a, trace a corresponds to
the spectrum of a cisplatin-treated sample after 72-h
incubation and trace b corresponds to the same sample after
addition of RAPTA-C. Figure 5b shows the analogous
regions of the spectrum for the region attributable to
cytochrome c adducts.
After 24 h following addition of RAPTA-C to the pro-
tein–cisplatin incubation mixture, apart from platinum–
protein adducts, only low-intensity signals corresponding
to ruthenium-bound species were detected for both ubiq-
uitin and cytochrome c at 8,796.6, corresponding to
ubiquitin–[Ru(g6-p-cymene)], and 12,750.4 Da, corre-
sponding to cytochrome c–[Ru(g6-p-cymene)pta]. In the
case of SOD only cisplatin adducts were detected (data not
shown), which is expected since RAPTA-C showed rela-
tively low binding to this protein in the absence of
cisplatin. Again, these data suggest that RAPTA-C com-
petes with cisplatin for the same binding sites on the three
selected proteins. It is worth noting that all the adducts
were assigned on the basis of comparisons between
observed and theoretical high-resolution MS spectra, which
are in excellent agreement. As an example, Fig. 6 shows
the ?7 charge state for the ubiquitin–Pt(NH3)2 and ubiq-
uitin–[Ru(g6-p-cymene)] adducts for a protein mixture
treated with excess cisplatin for 72 h and then reacted with
RAPTA-C for an additional 24 h (at 37 C). Figure S1
shows the theoretical and observed isotope patterns of the
cytochrome c–[Ru(g6-p-cymene)(pta)] adduct in the same
sample at charge state ?9.
The same type of competition experiment was repeated
by treating the mixture of proteins first with RAPTA-C and
then with cisplatin. Again, a limited number of platinum
adducts were detected for cytochrome c only, confirming
that the platinum complex competes with the organome-
tallic ruthenium compound for the same binding sites on
the proteins (see Fig. S2). Previous studies on the deter-
mination of the protein binding sites of metal complexes
employed the MS identification of peptides cleaved by
proteases (e.g. trypsin or Asp-N) [32]. In addition, chem-
ical modifications of specific residues on the protein side
chain (e.g. Met oxidation) before addition of the metal
complex have been used to confirm binding sites. For
cisplatin the preferential site on cytochrome c and ubiquitin
Table 2 Main peaks identified in the deconvoluted mass spectra of
RAPTA-C-treated protein mixtures after 3-, 6- and 12-h incubation at
37 C
Time (h) Mass (Da) Protein/RAPTA-C adduct
3 8,798.6 Ub–[Ru(g6-p-cymene)]
8,953.7 Ub–[Ru(g6-p-cymene)(pta)]
12,749.4 Cyt c–[Ru(g6-p-cymene)(pta)]
6 8,797.6 Ub–[Ru(g6-p-cymene)]
8,953.7 Ub–[Ru(g6-p-cymene)(pta)]
12,592.3 Cyt c–[Ru(g6-p-cymene)]
12,749.4 Cyt c–[Ru(g6-p-cymene)(pta)]
12 8,797.7 Ub–[Ru(g6-p-cymene)]
8,953.7 Ub–[Ru(g6-p-cymene)(pta)]
9,187.7 Ub–[Ru(g6-p-cymene)(pta)]
? Ub–[Ru(g6-p-cymene)]
9,223.7 Ub–[Ru(g6-p-cymene)(pta)Cl]
? Ub–[Ru(g6-p-cymene)]
12,592.3 Cyt c–[Ru(g6-p-cymene)]
12,749.4 Cyt c–[Ru(g6-p-cymene)(pta)]
12,983.4 Cyt c–[Ru(g6-p-cymene)(pta)]
? cyt c–[Ru(g6-p-cymene)]
766 J Biol Inorg Chem (2009) 14:761–770
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Fig. 4 LTQ-Orbitrap ESI mass spectra of the protein mixture treated
with cisplatin and RAPTA-C (5:1 metal-to-protein ratio) in TMeA-
mAc buffer pH 7.4 after 24 and 48 h. a The region of the spectrum
concerning the Ub adducts. b The region of the spectrum concerning
the cyt c adducts
J Biol Inorg Chem (2009) 14:761–770 767
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appears to be a Met residue, with the His residues being
secondary target sites [21, 45]. Nevertheless, the presence
of multiple adducts in the spectra indicates that several
residues in the proteins might be involved.
It would appear that the target residues correspond to
those that are more exposed on the surface of the protein
and therefore easily accessible for metal binding. So, for
example, X-ray structural data on cisplatin-treated SOD
unambiguously reveal a preference of platinum binding for
His compared with Met or Cys residues [46]. This prefer-
ence may be, at least in part, ascribed to the fact that access
to either Met-115 or Cys-6, the only ‘‘free’’ sulphur-con-
taining groups of SOD are somehow sterically hindered;
conversely Cys-55 and Cys-144, both solvent-accessible,
are engaged in the formation of an internal disulphide
bridge and are therefore less prone to react with a metal
complex.
Thus far, no definite protein binding sites have been
assigned for RAPTA-C, although some His residues have
been tentatively proposed for ruthenium compounds [47,
48]. Here, we showed that the primary target amino acids
appear to be the same for both cisplatin and RAPTA-C.
Since RAPTA-C is the only metal compound to show
selective protein binding, it is not unreasonable to attribute
this feature to the greater steric demand imposed by
RAPTA-C and possible hydrophobic interactions induced
by the arene ring, thereby increasing the selectivity of such
organometallic compounds relative to simple coordination
complexes. The implications of such interactions are likely
to be important in future drug design.
Conclusions
High-resolution MS coupled with a ‘‘soft’’ ionisation
method, i.e. ESI MS, provides detailed information on
metallodrug–protein interactions that give fundamental
insights into their modes of action. In the present study, the
Fig. 5 LTQ-Orbitrap ESI mass spectra of the protein mixture treated
with cisplatin (5:1 metal-to-protein ratio) in TMeAmAc buffer pH 7.4
before (trace a) and 24 h after addition of RAPTA-C (5:1 metal-to-
protein ratio) (trace b). a The region of the spectrum concerning the
Ub adducts. b The region of the spectrum concerning the cytochrome
c adducts
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reactivity of representative metallodrugs with a mixture of
proteins was probed without using any chromatographic
separation prior to analysis.
Differences in the selectivity of the various metal
complexes were readily identified using this approach. In
particular, cisplatin was moderately reactive towards the
proteins without any discrimination/selectivity, whereas
RAPTA-C was considerably more reactive and could
also discriminate between ubiquitin/cytochrome c and
SOD. Such information has important implications for
the mode of action of the metallodrugs in the cell and
presumably also for their toxic side effects. Once actual
protein targets have been established, it would be inter-
esting to screen them in the presence of other proteins,
as described here, to provide an indication of their
selectivity.
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